RT Journal Article
SR Electronic
T1 Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.25.21258374
DO 10.1101/2021.06.25.21258374
A1 Gomez, Felicia
A1 Mosior, Matthew
A1 McMichael, Joshua
A1 Skidmore, Zachary L.
A1 Duncavage, Eric J.
A1 Miller, Christopher A.
A1 Abel, Haley J.
A1 Li, Yi-Shan
A1 Krysiak, Kilannin
A1 Russler-Germain, David A.
A1 Watkins, Marcus P.
A1 Ramirez, Cody
A1 Schmidt, Alina
A1 Rodrigues, Fernanda Martins
A1 Trani, Lee
A1 Khanna, Ajay
A1 Wagner, Julia A.
A1 Fulton, Robert S.
A1 Fronick, Catrina
A1 O’Laughlin, Michelle
A1 Schappe, Timothy
A1 Cashen, Amanda
A1 Mehta-Shah, Neha
A1 Kahl, Brad S.
A1 Walker, Jason
A1 Bartlett, Nancy L.
A1 Griffith, Malachi
A1 Fehniger, Todd A.
A1 Griffith, Obi L.
YR 2021
UL http://medrxiv.org/content/early/2021/07/04/2021.06.25.21258374.abstract
AB The malignant Hodgkin and Reed Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) are scarce in affected lymph nodes, creating a challenge to detect driver somatic mutations. As an alternative to cell purification techniques, we hypothesized that ultra-deep exome sequencing would allow genomic study of HRS cells, thereby streamlining analysis and avoiding technical pitfalls. To test this, 31 cHL tumor/normal pairs were exome sequenced to ∼1000x median depth of coverage. An orthogonal error-corrected sequencing approach verified >95% of the discovered mutations. We identified mutations in genes novel to cHL including: CDH5 and PCDH7; novel mutations in IL4R, and a novel pattern of recurrent mutations in pathways regulating Hippo signaling. This study provides proof-of-principle that ultra-deep exome sequencing can be utilized to identify recurrent mutations in HRS cells, allowing for the analysis for clinically relevant genomic variants in large cohorts of cHL patients.Competing Interest StatementNLB has research funding from ADC Therapeutics, Affimed, Autolus, Bristol-Myers Squibb, Celgene, Forty Seven, Immune Design, Janssen, Kite Pharma/Gilead, Merck, Millennium, Pharmacyclics, Pfizer, Roche/Genentech, and SeaGen, and has been on advisory boards for ADC Therapeutics, Roche/Genentech, and SeaGen. NMS has research funding from Bristol-Myers Squibb, Secura Bio, Genentech/Roche, Innate Pharmaceuticals, Astra Zeneca, Celgene, Corvus Pharmaceuticals. NMS has served as a consultant for Kiowa Hakka Kirin, C4 therapeutics, Secura Bio, Ono Pharmaceuticals, Daiichi Sankyo, Karyopharma.Funding StatementThe authors thank Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes Jewish Hospital and the Institute of Clinical and Translational Sciences (ICTS) at Washington University for the use of the Tissue Procurement Core which provided DNA isolation services. The Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant #P30 CA091842 and the ICTS is funded by the National Institutes of Healths NCATS Clinical and Translational Science Award (CTSA) program grant UL1 TR002345. The authors thank Grace Triska for her help with early clinical data organization. M.G. was supported by a National Institutes of Health National Human Genome Research Institute grant (K99 HG007940). O.L.G. was supported by National Institutes of Health National Cancer Institute grants (U01 CA209936 U24 CA237719 and K22 CA188163). This work was supported by the Siteman Investment Program Team Science Award (TAF BK) the Larry and Winnie Chiang Lymphoma Fellowship (T.A.F. F.G.) the Paul Calabresi Career Development Award (K12 5K12CA167540 F.G.) the Siteman Cancer Center Research Development Award (T.A.F.) and the Foundation for Barnes-Jewish Hospital Steinback Fund (N.L.B.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients provided written informed consent for the use of their samples in sequencing as part of the Washington University School of Medicine (WUSM) Lymphoma Banking Program. The WUSM Institutional Review Board (IRB) approved protocols include: IRB 201108251, 201104048, 201110187. All human research activities are guided by the ethical principles in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects Research of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw de-identified exome sequences described in this analysis will be deposited in the NCBI sequence read archive (SRA) via dbGaP under the accession phs001229